Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Hematología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
INTERVENTIONAL
Inicio: 5 de nov de 2012
ID: NCT01750190
Completado
Fase 3
ClinicalTrials.gov
Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)
INTERVENTIONAL
Inicio: 1 de feb de 2016
ID: NCT02680574
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
INTERVENTIONAL
Inicio: 1 de nov de 2008
ID: NCT00809965
Terminado
Fase 2
ClinicalTrials.gov
Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00623727
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
INTERVENTIONAL
Inicio: 24 de oct de 2023
ID: NCT05949684
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
INTERVENTIONAL
Inicio: 8 de jul de 2014
ID: NCT02125877
Reclutando
ClinicalTrials.gov
Identificación de la relación Entre Componentes de la Inmunidad Celular y Factores Inflamatorios y neuroendócrinos Como Determinantes Del pronóstico clínico en el síndrome Coronario Agudo
OBSERVATIONAL
Inicio: 1 de ene de 2024
ID: NCT06513611
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
INTERVENTIONAL
Inicio: 13 de nov de 2017
ID: NCT03251482
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
INTERVENTIONAL
Inicio: 12 de feb de 2019
ID: NCT03797326
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
INTERVENTIONAL
Inicio: 5 de abr de 2021
ID: NCT04728893
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
INTERVENTIONAL
Inicio: 26 de jun de 2014
ID: NCT02174627
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)
INTERVENTIONAL
Inicio: 1 de mar de 2007
ID: NCT00423319
Completado
Fase 3
ClinicalTrials.gov
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
INTERVENTIONAL
Inicio: 1 de dic de 2009
ID: NCT01029340
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Controlled, Open-Label, Multi-Centre, Parallel-Group Study To Assess All-Cause Mortality And Cardiovascular Morbidity In Patients With Chronic Kidney Disease On Dialysis And Those Not On Renal Replacement Therapy Under Treatment With MIRCERA® Or Reference ESAs.
INTERVENTIONAL
Inicio: 12 de dic de 2008
ID: NCT00773513
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A
INTERVENTIONAL
Inicio: 29 de may de 2013
ID: NCT01775618
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
INTERVENTIONAL
Inicio: 17 de jul de 2009
ID: NCT00858364
Completado
ClinicalTrials.gov
Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma. Prospective Randomized Controlled Trial.
INTERVENTIONAL
Inicio: 3 de ene de 2021
ID: NCT04703998
Completado
Fase 4
ClinicalTrials.gov
Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial
INTERVENTIONAL
Inicio: 1 de ene de 2010
ID: NCT01064284
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
INTERVENTIONAL
Inicio: 16 de dic de 2020
ID: NCT04687072
Completado
ClinicalTrials.gov
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
INTERVENTIONAL
Inicio: 4 de abr de 2017
ID: NCT03023020
Anterior
1
...
7
8
9
...
434
Siguiente
Filtros